Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$46.50 -0.9%	$47.69	$39.50 ▼ $63.33	$95.49B	0.36	12.82 million shs	10.68 million shs
GILD Gilead Sciences	$111.78 +0.0%	$107.12	$66.34 ▼ $119.96	$139.01B	0.29	7.67 million shs	6.96 million shs
JNJ Johnson & Johnson	$155.23 -0.5%	$153.67	$140.68 ▼ $169.99	$375.37B	0.41	8.02 million shs	6.26 million shs
PFE Pfizer	$25.23 -0.6%	$23.76	$20.92 ▼ $31.54	$144.29B	0.58	41.53 million shs	34.89 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-1.10%	+0.32%	-3.97%	-12.21%	+17.25%
GILD Gilead Sciences	+0.45%	+0.82%	-0.60%	+8.32%	+67.61%
JNJ Johnson & Johnson	-0.43%	+1.74%	+0.14%	+4.02%	+5.97%
PFE Pfizer	-0.84%	+3.96%	+8.01%	+16.03%	-10.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol Myers Squibb	4.8993 of 5 stars	3.2	3.0	4.2	4.0	2.8	3.3	1.3
GILD Gilead Sciences	4.8297 of 5 stars	1.4	3.0	4.2	4.1	4.0	2.5	3.1
JNJ Johnson & Johnson	4.9561 of 5 stars	3.3	5.0	4.2	3.9	3.0	1.7	1.9
PFE Pfizer	4.9738 of 5 stars	3.2	3.0	4.2	4.5	2.8	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.32	Hold	$58.00	24.73% Upside
GILD Gilead Sciences	2.77	Moderate Buy	$111.38	-0.36% Downside
JNJ Johnson & Johnson	2.55	Moderate Buy	$170.88	10.08% Upside
PFE Pfizer	2.45	Hold	$28.55	13.16% Upside

Current Analyst Ratings Breakdown

Latest JNJ, PFE, BMY, and GILD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/21/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00
5/13/2025	JNJ Johnson & Johnson	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$169.00 ➝ $153.00
4/30/2025	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform	$22.00 ➝ $23.00
4/30/2025	PFE Pfizer	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral	$29.00 ➝ $27.00
4/30/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral	$26.00 ➝ $27.00
4/30/2025	PFE Pfizer	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform	$28.00 ➝ $26.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$47.64B	1.99	$5.83 per share	7.97	$8.08 per share	5.75
GILD Gilead Sciences	$28.75B	4.84	$6.87 per share	16.27	$15.44 per share	7.24
JNJ Johnson & Johnson	$89.33B	4.18	$13.06 per share	11.89	$29.69 per share	5.23
PFE Pfizer	$62.46B	2.30	$4.34 per share	5.82	$15.62 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.42	7.64	1.39	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	23.53	13.78	0.72	20.76%	51.93%	17.40%	8/6/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$8.99	17.27	14.02	2.36	24.42%	33.46%	13.30%	7/16/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.28	8.33	0.92	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest JNJ, PFE, BMY, and GILD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.53	N/A	N/A	N/A	$11.32 billion	N/A
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.65	N/A	N/A	N/A	$22.85 billion	N/A
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion
4/15/2025	Q1 2025	JNJ Johnson & Johnson	$2.59	$2.77	+$0.18	$4.54	$21.65 billion	$21.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.33%	N/A	92.88%	17 Years
GILD Gilead Sciences	$3.16	2.83%	N/A	66.53%	10 Years
JNJ Johnson & Johnson	$5.20	3.35%	N/A	57.84%	64 Years
PFE Pfizer	$1.72	6.82%	N/A	124.64%	16 Years

Latest JNJ, PFE, BMY, and GILD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
4/15/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.37%	5/27/2025	5/27/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.65	1.28	1.17
GILD Gilead Sciences	1.16	1.37	1.23
JNJ Johnson & Johnson	0.49	1.26	1.03
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
GILD Gilead Sciences	83.67%
JNJ Johnson & Johnson	69.55%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.09%
GILD Gilead Sciences	0.27%
JNJ Johnson & Johnson	0.16%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

JNJ, PFE, BMY, and GILD Headlines

Recent News About These Companies

Pfizer Inc. (NYSE:PFE) Shares Purchased by TD Private Client Wealth LLC

2 hours ago | marketbeat.com

Envestnet Asset Management Inc. Purchases 1,231,296 Shares of Pfizer Inc. (NYSE:PFE)

3 hours ago | marketbeat.com

Mphasis, 6 other stocks to trade ex-dividend tomorrow. Last opportunity to buy for benefit

July 7 at 10:41 PM | economictimes.indiatimes.com

Will The Tariff “Taco Trade” End The Rally? 5 High-Yield Value Stocks Are Strong Buys Now

July 7 at 2:35 PM | 247wallst.com

Top 5 Undervalued Dividend Stocks With Strong Payout Potential (PFE)

...

July 7 at 10:38 AM | marketbeat.com

Davidson Investment Advisors Increases Holdings in Pfizer Inc. (NYSE:PFE)

July 7 at 8:30 AM | marketbeat.com

Planning Directions Inc. Acquires Shares of 96,107 Pfizer Inc. (NYSE:PFE)

July 7 at 8:09 AM | marketbeat.com

U.S. Capital Wealth Advisors LLC Raises Position in Pfizer Inc. (NYSE:PFE)

July 7 at 7:25 AM | marketbeat.com

Capital Advisors Inc. OK Raises Stock Position in Pfizer Inc. (NYSE:PFE)

July 7 at 6:21 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Financiere des Professionnels Fonds d investissement inc.

July 6 at 9:05 AM | marketbeat.com

Concurrent Investment Advisors LLC Raises Holdings in Pfizer Inc. (NYSE:PFE)

July 6 at 6:59 AM | marketbeat.com

World Investment Advisors Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

July 6 at 6:48 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Stock Position Decreased by Truist Financial Corp

July 6 at 6:31 AM | marketbeat.com

Quattro Financial Advisors LLC Sells 95,781 Shares of Pfizer Inc. (NYSE:PFE)

July 5 at 8:51 AM | marketbeat.com

Adell Harriman & Carpenter Inc. Acquires 139,829 Shares of Pfizer Inc. (NYSE:PFE)

July 5 at 8:51 AM | marketbeat.com

HM Payson & Co. Sells 38,767 Shares of Pfizer Inc. (NYSE:PFE)

July 5 at 8:33 AM | marketbeat.com

Bank of New York Mellon Corp Sells 1,177,185 Shares of Pfizer Inc. (NYSE:PFE)

July 5 at 8:26 AM | marketbeat.com

Generali Investments CEE investicni spolecnost a.s. Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

July 5 at 8:10 AM | marketbeat.com

Ceera Investments LLC Buys 11,105 Shares of Pfizer Inc. (NYSE:PFE)

July 5 at 7:57 AM | marketbeat.com

Capital Investment Advisory Services LLC Has $5.36 Million Stake in Pfizer Inc. (NYSE:PFE)

July 5 at 7:16 AM | marketbeat.com

The Best Dividend Stocks I'd Buy Right Now

July 5 at 6:30 AM | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
By Ryan Hasson | July 7, 2025
View Top 5 Undervalued Dividend Stocks With Strong Payout Potential

JNJ, PFE, BMY, and GILD Company Descriptions

Bristol Myers Squibb NYSE:BMY

$46.50 -0.42 (-0.90%)

Closing price 07/7/2025 03:59 PM Eastern

Extended Trading

$46.58 +0.08 (+0.17%)

As of 08:02 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Gilead Sciences NASDAQ:GILD

$111.78 +0.03 (+0.03%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$111.84 +0.06 (+0.05%)

As of 08:03 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Johnson & Johnson NYSE:JNJ

$155.23 -0.78 (-0.50%)

Closing price 07/7/2025 03:59 PM Eastern

Extended Trading

$155.21 -0.02 (-0.02%)

As of 08:02 AM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Pfizer NYSE:PFE

$25.23 -0.15 (-0.59%)

Closing price 07/7/2025 03:59 PM Eastern

Extended Trading

$25.22 -0.02 (-0.06%)

As of 08:03 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time